Immune checkpoint inhibitors induce immune-mediated myocarditis and inflammasome activation in a tumor-bearing mouse model

Clicks: 1
ID: 323381
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #173 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Immune checkpoint inhibitor–associated myocarditis (ICI-M) is the most severe complication produced by ICIs. Although rare (1–2% of patients), ICI-M carries a high mortality rate (25–40%) and frequently presents with life-threatening arrhythmias and conduction disorders. ICI-M is characterized by myocardial infiltration of CD4⁺/CD8⁺ T lymphocytes and macrophages, leading to myocardial necrosis, with strong activation of interferon-γ signaling and the NLRP3 inflammasome. Mechanisms driving immune cell recruitment to the myocardium remain poorly understood, and current in vivo models only partially address disease complexity, particularly the contribution of myocardial endothelial dysfunction. Objective This study aims to investigate immune checkpoint inhibitor–associated myocarditis in vivo and to dissect the cellular and molecular mechanisms driving immune-mediated myocardial injury using a murine model involving tumor burden and ICI treatment. Method The ICI-M model was generated by subcutaneous injection of murine melanocytic cells into BALB/c mice and subsequent combined anti–PD-1/anti–CTLA-4 therapy. Four groups were formed: saline-treated controls (PHY), tumor-bearing mice treated with saline (K+PHY), tumor-bearing mice treated with IgG (K+IgG), and tumor-bearing mice treated with ICIs (K+ICI). Electrocardiograms were recorded and cardiac tissues collected for immunohistological and molecular analyses. Results Compared with IgG controls, ICI treatment reduced tumor volume by 85% (p<0.01) and induced marked myocardial immune infiltration, with increased CD3⁺ T cells (3.1% vs 0.4%, p<0.001) and CD68⁺ macrophages (2.9% vs 2.1%, p<0.05), together with PD-L1 overexpression (2.5% vs 1.5%, p<0.05). PD-L1 expression was also increased in IgG-treated animals but immune infiltration was absent, suggesting non-specific immune activation. ICI treatment induced pronounced electrophysiological alterations with reduced QRS and T wave amplitudes, QT interval shortening, cardiac axis deviation (Lewis index), and QRS prolongation. Molecular analyses revealed activation of the NLRP3 inflammasome pathway in tumor-bearing ICI-treated mice vs control mice, with increased GBP5 (3.0% vs 1.4%, p<0.001) and CASPASE-1 (3,1% vs 1.2%, p<0.001) expression. Aim2 expression was increased by 9.1% in tumor-bearing mice (p<0.001) while endothelial activation, monitored using CD31 overexpression (11.4%, p<0.01), was solely observed in ICI-treated mice. Conclusion Immune checkpoint inhibitors induce myocardial immune infiltration associated with specific electrophysiological abnormalities of ICI-associated myocarditis. In addition to confirming NLRP3 inflammasome involvement, these findings identify myocardial endothelial injury, likely driven by AIM2 inflammasome activation as a key mechanism of immune-mediated myocarditis. These results indicate that our tumor-bearing model may help to address the pathophysiology of ICI-related cardiotoxicity.
Reference Key
openalex_W7172283241 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors S Lledo, T T Tran, A Timili, J Ciccolini, E Fenouillet, F Thuny, J Cautela, N Lalevee
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.232
URL
https://doi.org/10.1093/eurheartjsupp/suag097.232
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.